LivaNova (NASDAQ:LIVN) Stock Crosses Below 50 Day Moving Average of $57.89

LivaNova PLC (NASDAQ:LIVN)’s stock price crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $57.89 and traded as low as $52.75. LivaNova shares last traded at $52.89, with a volume of 546,551 shares changing hands.

Analysts Set New Price Targets

A number of brokerages have issued reports on LIVN. StockNews.com raised LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Needham & Company LLC restated a “buy” rating and issued a $72.00 target price on shares of LivaNova in a report on Thursday, June 6th. Robert W. Baird increased their price target on shares of LivaNova from $58.00 to $66.00 and gave the stock a “neutral” rating in a research note on Thursday, May 2nd. Finally, Mizuho boosted their price objective on shares of LivaNova from $75.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $66.20.

LivaNova Trading Down 2.9 %

The company has a debt-to-equity ratio of 0.50, a current ratio of 3.17 and a quick ratio of 2.71. The business’s 50-day simple moving average is $57.89 and its two-hundred day simple moving average is $54.25. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of -88.15 and a beta of 0.99.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 1st. The company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.28. LivaNova had a negative net margin of 2.68% and a positive return on equity of 13.59%. The business had revenue of $294.90 million for the quarter, compared to the consensus estimate of $278.17 million. During the same quarter last year, the firm posted $0.43 EPS. The business’s revenue for the quarter was up 12.0% compared to the same quarter last year. On average, research analysts anticipate that LivaNova PLC will post 2.6 earnings per share for the current fiscal year.

Insider Activity at LivaNova

In other LivaNova news, Director Daniel Jeffrey Moore sold 56,623 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $60.11, for a total value of $3,403,608.53. Following the completion of the sale, the director now owns 27,534 shares of the company’s stock, valued at $1,655,068.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.27% of the company’s stock.

Institutional Trading of LivaNova

Large investors have recently modified their holdings of the business. Norges Bank purchased a new position in LivaNova in the fourth quarter valued at about $26,064,000. Ameriprise Financial Inc. boosted its stake in shares of LivaNova by 96.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 916,632 shares of the company’s stock valued at $48,471,000 after buying an additional 449,136 shares during the last quarter. Mesirow Institutional Investment Management Inc. acquired a new stake in shares of LivaNova during the first quarter worth approximately $13,816,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of LivaNova in the fourth quarter worth $8,330,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in LivaNova in the third quarter valued at $7,932,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.